Related Experiment Video
Updated: Jan 22, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
Published on: August 25, 2017
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma
Javier Martin-Broto1,2,3, Antonio Casado4, Gloria Marquina4
1Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain. jmartin@atbsarc.org.
Abstract:
Exportin-1 (XPO-1) is related to drug resistance and poor prognosis in solid tumors. Selinexor, an XPO-1 inhibitor, has shown preclinical and clinical activity in sarcomas. This Phase I study explores the combination of gemcitabine and selinexor in a classic 3 + 3 design. Adult patients with selected advanced sarcomas receive gemcitabine and weekly selinexor in 21-day cycles. The main endpoint is to determine the recommended phase 2 dose (RP2D). Secondary end-points include safety, overall response rate (ORR), overall survival (OS), and quality of life. Seventeen patients are included in this study. One dose-limiting toxicity (grade 4 thrombocytopenia) is detected in dose-level +3, but the R2PD is established at dose-level +2 (gemcitabine at 1200 mg/m² at 10 mg/m²/min followed by 60 mg weekly selinexor) based on its better tolerability. The most frequent adverse events are neutropenia (82.4%) and thrombocytopenia (76.5%). The ORR is 31.25 %, and the median OS (mOS) is 39.5 months (95% CI, 12.4-67) with a 36-month OS rate of 50.2%. A phase II is currently exploring this combination in leiomyosarcoma and malignant peripheral nerve sheath tumors. Trial registration: NCT04595994.
Insights
This Phase I study found that combining gemcitabine with selinexor is a tolerable treatment for advanced sarcomas, establishing a recommended dose for further trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- Exportin-1 (XPO-1) is implicated in solid tumor drug resistance and poor prognosis.
- Selinexor, an XPO-1 inhibitor, demonstrates preclinical and clinical efficacy in sarcomas.
Purpose of the Study:
- To determine the recommended Phase 2 dose (RP2D) of combination gemcitabine and selinexor in advanced sarcomas.
- To evaluate the safety, efficacy, and quality of life associated with this combination therapy.
Main Methods:
- A Phase I, classic 3+3 dose-escalation study.
- Adult patients with advanced sarcomas received gemcitabine and weekly selinexor over 21-day cycles.
- Seventeen patients were enrolled to assess dose-limiting toxicities and establish the RP2D.
Main Results:
- The recommended Phase 2 dose (RP2D) was established at dose-level +2: gemcitabine (1200 mg/m²) and weekly selinexor (60 mg), due to better tolerability.
- The most frequent adverse events were neutropenia (82.4%) and thrombocytopenia (76.5%).
- An overall response rate (ORR) of 31.25% and a median overall survival (mOS) of 39.5 months were observed.
Conclusions:
- Combination gemcitabine and selinexor is a tolerable and potentially effective treatment for advanced sarcomas.
- A Phase II trial is ongoing to further investigate this combination in specific sarcoma subtypes like leiomyosarcoma and MPNST.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Phase Diagrams
Phase Transitions
What is Natural Selection?
Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...

